Niagen Bioscience

Niagen Bioscience (NASDAQ: NAGE), formerly ChromaDex, is the global authority on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging research. For over 25 years, the company has pioneered research into cellular health, developing clinically proven solutions that help people age better. Their flagship ingredient, Niagen® (nicotinamide riboside chloride), is one of the world's most extensively researched NAD+ precursors, backed by 40+ published, peer-reviewed human clinical studies and recognized by global regulatory bodies.

The company operates through two primary brands: Tru Niagen®, America's trusted NAD-boosting daily supplement proven to increase cellular NAD+ levels, and Niagen® Plus, which offers pharmaceutical-grade IV and injectable therapies for health enthusiasts seeking advanced treatments. With ISO-accredited laboratories, 50+ owned and licensed patents, and 300+ global research collaborations with leading institutions including Stanford, Harvard, and City of Hope, Niagen Bioscience sets the gold standard in scientific rigor. Guided by world-renowned scientists including Nobel laureates Dr. Roger Kornberg and Sir John Walker, the company continues to uncover the potential of NAD+ with precision science, developing innovative solutions for dietary supplements, skincare, food and beverage, and pharmaceutical markets.